MedPath

Iris Sommer

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

3 Phases

Phase 3:2
Phase 4:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Not Applicable
1 (25.0%)
Phase 4
1 (25.0%)

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

Phase 3
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder
Psychosis NOS
Interventions
Drug: Placebo
First Posted Date
2017-02-06
Last Posted Date
2021-10-08
Lead Sponsor
Iris Sommer
Target Recruit Count
110
Registration Number
NCT03043820
Locations
🇳🇱

UMC Utrecht, Utrecht, Netherlands

Understanding Hallucinations (Part II)

Conditions
Hallucinations
First Posted Date
2015-06-03
Last Posted Date
2016-10-26
Lead Sponsor
Iris Sommer
Target Recruit Count
240
Registration Number
NCT02460965
Locations
🇳🇱

UMC Utrecht, Utrecht, Netherlands

Simvastatin Addition for Patients With Recent-onset Schizophrenia

Phase 3
Completed
Conditions
Schizoaffective Disorder
Schizophreniform Disorder
Psychosis NOS
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2013-12-03
Last Posted Date
2020-10-19
Lead Sponsor
Iris Sommer
Target Recruit Count
121
Registration Number
NCT01999309
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations

Not Applicable
Conditions
Hearing Disorders
Personality Disorders
Stress Disorders, Post-Traumatic
Psychotic Disorders
Mood Disorders
First Posted Date
2013-11-06
Last Posted Date
2017-05-03
Lead Sponsor
Iris Sommer
Target Recruit Count
62
Registration Number
NCT01977521
Locations
🇳🇱

UMC, Utrecht, Netherlands

Effect of Methylphenidate on Connectivity

Phase 4
Withdrawn
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Other: Placebo
First Posted Date
2013-01-09
Last Posted Date
2014-02-26
Lead Sponsor
Iris Sommer
Registration Number
NCT01764672
Locations
🇳🇱

UMC Utrecht, Utrecht, Netherlands

News

No news found
© Copyright 2025. All Rights Reserved by MedPath